Cargando…

Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”

Detalles Bibliográficos
Autor principal:	Singh, S. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838895/ https://www.ncbi.nlm.nih.gov/pubmed/29535953 http://dx.doi.org/10.4103/ijem.IJEM_22_18

Ejemplares similares

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sulfonylurea action re‐revisited
por: Seino, Susumu, et al.
Publicado: (2010)

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

ATP and Sulfonylurea Linkage in the K(ATP) Channel Solves a Diabetes Puzzler
por: Drain, Peter
Publicado: (2013)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
por: Hwang, You-Cheol
Publicado: (2015)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
por: Shimoda, Masashi, et al.
Publicado: (2016)

The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
por: Yu, Miao
Publicado: (2020)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Sulfonylureas in the Treatment of Type 2 Diabetes Mellitus: A Fresh Look and New Insights
por: Alzaid, Aus
Publicado: (2020)

Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus
por: Paz-Pacheco, Elizabeth, et al.
Publicado: (2022)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
por: Min, Se Hee, et al.
Publicado: (2015)

Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Initial Sulfonylurea Use and Subsequent Insulin Therapy in Older Subjects with Type 2 Diabetes Mellitus
por: Fu, Alex Z., et al.
Publicado: (2012)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Sulfonylureas: Assets in the past, present and future
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sulfonylureas: Scoring beyond START STUDY
por: Shaikh, Altamash
Publicado: (2017)

Sulfonylurea and neuroprotection: The bright side of the moon
por: Hussien, Nawar R., et al.
Publicado: (2018)

The Place of Sulfonylureas in Guidelines: Why Are There Differences?
por: Amod, Aslam
Publicado: (2020)

Latest Evidence on Sulfonylureas: What’s New?
por: Leiter, Lawrence A.
Publicado: (2020)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
por: Srivanichakorn, Weerachai, et al.
Publicado: (2015)

Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes
por: Heaton, Pamela C., et al.
Publicado: (2016)

Management of sulfonylurea‐treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer
por: Shepherd, M., et al.
Publicado: (2017)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Relapsed 6q24-related transient neonatal diabetes mellitus successfully treated with sulfonylurea
por: Fu, Jun-Ling, et al.
Publicado: (2019)

Remission of Severe Neonatal Diabetes With Very Early Sulfonylurea Treatment
por: Marshall, Bess A., et al.
Publicado: (2015)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
por: Das, Ashok Kumar, et al.
Publicado: (2023)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1kal1cm2imbud59erblmqetjv4